Company: VCYT
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001384101-25-000130
Chunk: 104

Company: VERACYTE, INC.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 8
Chunk 104
---
487 1,216 271 22 %Other expenses4,326 919 3,407 371 %7,830 3,520 4,310 122 %Allocations3,204 2,939 265 9 %9,989 8,694 1,295 15 %Total$33,777 $29,029 $4,748 16 %$94,444 $82,928 $11,516 14 %Cost of product revenue:        Product costs$1,050 $545 $505 93 %$1,864 $2,436 $(572)(23)%License fees and royalties257 270 (13)(5)%888 1,021 (133)(13)%Depreciation and amortization110 222 (112)(50)%471 659 (188)(29)%Other expenses1,562 528 1,034 196 %2,509 1,713 796 46 %Allocations36 227 (191)(84)%454 481 (27)(6)%Total$3,015 $1,792 $1,223 68 %$6,186 $6,310 $(124)(2)%Cost of biopharmaceutical and other revenue:        Compensation expense$426 $1,424 $(998)(70)%$3,318 $4,958 $(1,640)(33)%License fees and royalties— — — NM— 150 (150)(100)%Depreciation and amortization10 48 (38)(79)%109 172 (63)(37)%Other expenses602 976 (374)(38)%3,009 2,922 87 3 %Allocations53 664 (611)(92)%925 1,560 (635)(41)%Total$1,091 $3,112 $(2,021)(65)%$7,361 $9,762 $(2,401)(25)%Intangible asset amortization - cost of revenue$2,707 $2,917 $(210)(7)%$7,959 $8,741 $(782)(9)%

Cost of testing revenue increased $4.7 million, or 16%, for the three months ended September 30,